Literature DB >> 6637831

Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension.

S Rich, R Ganz, P S Levy.   

Abstract

The effects of 3 types of vasoactive agents, hydralazine, nifedipine and amrinone, were evaluated in 7 patients with primary pulmonary hypertension (PPH). Hemodynamic values were measured before and after drug administration in every patient. All drugs increased cardiac output and reduced both systemic and pulmonary resistance in the patients studied. Only nifedipine significantly reduced pulmonary artery (PA) pressure (6 +/- 5 mm Hg). In addition, it decreased pulmonary resistance to a greater degree than systemic resistance in 2 of the 7 patients, suggesting that nifedipine can cause selective pulmonary vasodilation in some patients. Hydralazine appeared to increase cardiac output and stroke volume by reducing systemic resistance. There was no evidence of direct pulmonary vasodilating effects; it decreased systemic resistance more than pulmonary resistance in every case. The increase in cardiac output from amrinone was secondary to a decrease in systemic arterial pressure with reflex tachycardia; stroke volume was unchanged. Amrinone had little pulmonary effect in all but 1 patient, in whom it substantially reduced PA pressure and pulmonary resistance. The mechanism of action of these 3 drugs in PPH differs. Nifedipine holds the most promise as an effective pulmonary vasodilator. A study of the effects of long-term administration of nifedipine in PPH is warranted.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6637831     DOI: 10.1016/0002-9149(83)90541-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Acute pulmonary hypertension complicating the arterial switch procedure.

Authors:  J Freeman; S Y DeLeon; R H Miles; F X Downey; J Hofstra; J A Quinones; E A Fisher; R Pifarre
Journal:  Pediatr Cardiol       Date:  1995 Nov-Dec       Impact factor: 1.655

2.  The treatment of primary pulmonary hypertension.

Authors:  N G Uren; C M Oakley
Journal:  Br Heart J       Date:  1991-08

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

4.  Iron chelation inhibits the development of pulmonary vascular remodeling.

Authors:  Chi-Ming Wong; Ioana R Preston; Nicholas S Hill; Yuichiro J Suzuki
Journal:  Free Radic Biol Med       Date:  2012-08-25       Impact factor: 7.376

Review 5.  Pulmonary hypertension in children: perioperative management.

Authors:  F A Burrows; J R Klinck; M Rabinovitch; D J Bohn
Journal:  Can Anaesth Soc J       Date:  1986-09

6.  Sublingual isoprenaline in treatment of primary pulmonary hypertension: discussion paper.

Authors:  J F Ackroyd
Journal:  J R Soc Med       Date:  1985-06       Impact factor: 5.344

Review 7.  Epigenetic Mechanisms and Events in Gastric Cancer-Emerging Novel Biomarkers.

Authors:  Hasan Raza Kazmi; Soni Kumari; Satendra Tiwari; A Khanna; Gopeshwar Narayan
Journal:  Pathol Oncol Res       Date:  2018-03-19       Impact factor: 3.201

8.  Factors that influence the outcome of primary pulmonary hypertension.

Authors:  A Rozkovec; P Montanes; C M Oakley
Journal:  Br Heart J       Date:  1986-05

Review 9.  Epigenetic alterations in gastric cancer (Review).

Authors:  Du-Guan Fu
Journal:  Mol Med Rep       Date:  2015-05-22       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.